IBJNews

Lilly wins approval of antidepressant Cymbalta for pain

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly & Co. has won approval to sell the antidepressant Cymbalta, its second-biggest drug, as a treatment for pain.

The Food and Drug Administration cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions, the agency said Thursday in a prepared statement. An FDA advisory panel voted 8-6 in favor of Indianapolis-based Lilly’s application to expand Cymbalta use on Aug. 19.

Lilly is under pressure to maintain sales as its top drugs prepare for generic competition and new products struggle to reach the market. Broader approval of Cymbalta may provide only a small reprieve because the medicine’s patent expires in three years and it is already being prescribed as a painkiller, said Seamus Fernandez, an analyst at Leerink Swann & Co. in Boston.

“Half of that market opportunity could already be potentially accounted for,” Fernandez said in a telephone interview. He estimates annual sales of Cymbalta may increase by $500 million, or 16 percent, with approval for pain.

Sales of Cymbalta were $3.07 billion last year, accounting for 14 percent of Indianapolis-based Lilly’s revenue. The drug is scheduled to lose U.S. patent protection in 2013, along with the insulin Humalog, which ranks third in revenue. Top-selling Zyprexa, an antipsychotic, faces generic competition in 2011.

“Up to three-quarters of the population experience chronic pain at some time in their lives,” Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said in the statement. “This approval means that many of those people now have another treatment option.”

About 30 million patients have used Cymbalta since its initial approval for major depressive disorder in 2004, the agency said.

About 6.5 percent of Cymbalta prescriptions through last year were for headaches and nerve pain, including “chronic pain syndrome,” and 7 percent were for musculoskeletal system diseases, including arthritis and back pain, FDA staff said in a report released before the advisory panel meeting. While companies can’t promote drugs for uses not cleared by the FDA, doctors are allowed to prescribe them as they see appropriate.

Lilly asked for broad approval in chronic pain in the second quarter of 2008 before withdrawing the application after the FDA raised concerns about study design and statistical methodology. The application was resubmitted in June 2009.

An advisory panel review initially slated for January was canceled so regulators could have more time to consider new information pertaining to the drug’s “benefit-risk balance” in pain. Most of the advisers supported approval of the drug in August over concerns that it can cause liver damage and may not work for all patients. While the FDA usually follows its panels’ recommendations, it isn’t required to do so.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Can your dog sign a marriage license or personally state that he wishes to join you in a legal union? If not then no, you cannot marry him. When you teach him to read, write, and speak a discernible language, then maybe you'll have a reasonable argument. Thanks for playing!

  2. Look no further than Mike Rowe, the former host of dirty jobs, who was also a classically trained singer.

  3. Current law states income taxes are paid to the county of residence not county of income source. The most likely scenario would be some alteration of the income tax distribution formula so money earned in Marion co. would go to Marion Co by residents of other counties would partially be distributed to Marion co. as opposed to now where the entirety is held by the resident's county.

  4. This is more same-old, same-old from a new generation of non-progressive 'progressives and fear mongers. One only needs to look at the economic havoc being experienced in California to understand the effect of drought on economies and people's lives. The same mindset in California turned a blind eye to the growth of population and water needs in California, defeating proposal after proposal to build reservoirs, improve water storage and delivery infrastructure...and the price now being paid for putting the demands of a raucous minority ahead of the needs of many. Some people never, never learn..

  5. I wonder if I can marry him too? Considering we are both males, wouldn't that be a same sex marriage as well? If they don't honor it, I'll scream discrimination just like all these people have....

ADVERTISEMENT